Skip to content

Orexigen Therapeutics, Inc.

CIK 0001382911

← back to feed
Revenue (TTM)
$68.41M
+583.5% YoY Q3 Nov 2017
Net Income (TTM)
−$72.77M
−37.7% YoY Q3 Nov 2017
EPS Diluted (TTM)
−$1.00
Q3 Nov 2017
Gross Margin
72.2%
Q3 Nov 2017
Operating Margin
-111.2%
Q3 Nov 2017
Net Margin
-106.4%
Q3 Nov 2017
Free Cash Flow (TTM)
−$71.15M
Q3 Nov 2017
Cash
$45.58M
Q3 Nov 2017
Total Debt
$25.57M
Q3 Nov 2017
Shares Outstanding
16.6M sh
Q3 Nov 2017

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings